Examination for the effect of combination therapy with Eldecalcitol and Alendronate in primary osteoporotic patients

Examination for the effect of combination therapy with Eldecalcitol and Alendronate in primary osteoporotic patients - Examination for the effect of combination therapy with Eldecalcitol and Alendronate in primary osteoporotic patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008191

Enrollment

100

Registered

2012-06-18

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Alendronate (35mg/week) + Eldecalcitol (0.75ug/day) for 48 weeks Alendronate (35mg/week)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Primary osteoporotic patients 2.Patients who are treated with Alendronate for more than two years 3.Patients with informed of consent

Exclusion criteria

Exclusion criteria: 1. Patients who are diagnosed as contraindication of Alendronate treatments 2. Patients who are diagnosed as contraindication of Eldecalcitol treatments 3.Patients who have taken osteoporosis treatments other than Alendronate 4.Patients with cancer 5. Patients who are inappropriate for this study by physician

Design outcomes

Primary

Measure	Time frame
Change of lumbar spine bone mineral density	—

Countries

Japan

Contacts

Public ContactTakashi Nagai

Showa University Department of Orthopaedic Surgery

nagai.babby@gmail.com03-3784-8543

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026